6505--FY27 F18 Florebetapir
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
248-NETWORK CONTRACT OFFICE 8 (36C248)
Contract Value
Not provided
Codes & Classification
Solicitation Number
36C24826Q1256
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Department of Veterans Affairs, through its 248-Network Contract Office 8, has issued an award notice for the procurement of Florebetapir, as indicated by the notice titled "6505--FY27 F18 Florebetapir." This procurement falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, denoting Drugs and Biologicals. The notice is currently active and was posted on June 11, 2026.
The primary objective of this procurement is to secure a reliable supply of Florebetapir (F18), a radiopharmaceutical agent commonly used in positron emission tomography (PET) imaging, for the fiscal year 2027. The intended outcome is to ensure that the Department of Veterans Affairs has consistent access to this critical pharmaceutical product to support diagnostic imaging services for veterans. The scope of the contract likely includes the manufacturing, quality assurance, and timely delivery of Florebetapir to designated VA medical facilities, although specific delivery locations and quantities are not detailed in the notice.
Key requirements for this procurement would include compliance with all applicable federal regulations governing pharmaceutical manufacturing, as well as adherence to quality and safety standards necessary for radiopharmaceuticals. Contractors must be capable of producing Florebetapir (F18) to the specifications required for clinical use and must demonstrate the ability to meet the VA’s supply needs throughout the contract period.
The contracting activity is managed by the 248-Network Contract Office 8, a federal office within the Department of Veterans Affairs. The primary point of contact for this procurement is Benjamin M. Amato, who can be reached via email at [email protected] or by phone at 407-646-4005. Interested parties are encouraged to review the full notice and any associated attachments available on SAM.gov using the Opportunity ID 2c3db744f2bf4da2bdda3f7cc48b10df for further details.
This procurement is classified as an award notice, indicating that the contract has already been awarded. There is no information provided regarding set-aside requirements or special considerations such as small business preferences. Contractors evaluating similar future opportunities should note the importance of possessing the necessary manufacturing capabilities, regulatory compliance, and experience in supplying radiopharmaceuticals to federal healthcare entities.
Overall, this notice reflects the VA’s ongoing commitment to providing advanced diagnostic resources for veterans by securing essential pharmaceutical products through established federal procurement channels.